Table 3.

Treatment effects: subjective and clinical global impression (CGI) ratings at baseline, pergolide crossover period (0.50 ± 0.17 mg), and follow-up (0.37 ± 0.15 mg pergolide) (n = 22)

Efficacy criteriaBaselineEnd-of-study pergolideFollow-upp Value FU vs BLp Value FU vs PGL
Values are expressed as mean ± SD.
* Scale 1–5; 1 = bad, 5 = good.
† Scale 0–10; 0 = not at all, 10 = severe.
‡ Scale 0–50; 50 = high.
§ Scale 1–7; 7 = extremely ill.
FU = follow-up; BL = baseline; PGL = pergolide at end of crossover period; RLS = restless legs syndrome.
Patients’ sleep questionnaire*
Quality of sleep2.2 ± 0.83.1 ± 0.92.7 ± 0.70.00990.0820
Patients’ sleep diary
Sleep onset latency, min143.9 ± 105.573.3 ± 150.149.7 ± 40.20.00030.4021
No. of awakenings2.1 ± 1.51.5 ± 0.72.0 ± 0.90.73720.0244
Total sleep time, h5.4 ± 1.77.3 ± 1.07.2 ± 0.80.00011.000
Urge to move
At sleep onset5.9 ± 3.10.8 ± 1.51.8 ± 2.40.00010.0401
During the night6.5 ± 2.50.8 ± 1.61.7 ± 1.60.00010.0049
During the day3.2 ± 2.51.1 ± 1.52.6 ± 1.90.36310.0091
Patients’ ratings of severity of RLS
At sleep onset5.3 ± 3.20.5 ± 0.91.2 ± 2.90.00010.0586
During the night7.0 ± 2.90.4 ± 0.71.8 ± 2.00.00010.0009
During the day2.1 ± 2.40.5 ± 0.92.1 ± 2.40.98910.0024
Global4.8 ± 2.20.5 ± 0.561.7 ± 1.540.00010.0002
Quality of life
Life satisfaction26.5 ± 5.533.4 ± 5.530.1 ± 6.40.00090.0246
Negative feelings and complaints19.8 ± 6.213.3 ± 5.016.7 ± 7.00.05750.0125
CGI
Severity of illness§5.1 ± 0.92.3 ± 1.02.6 ± 0.90.00010.4892